
To describe and zzso the safety data from the zzso clinical development zzso 

In the 18 clinical studies zzso the clinical program, doses ranging from zzso to zzso zzso were administered to healthy adult volunteers, patients with zzso or zzso zzso and patients with confirmed or highly suspected central nervous system zzso liver, breast, zzso bone, or soft tissue zzso A total of zzso injections of zzso zzso or zzso were administered to zzso zzso Safety assessments were performed at appropriate intervals during all Phase 1, 2, and 3 zzso 

Of the zzso subjects exposed to a study drug or zzso in the clinical development program, zzso subjects experienced zzso adverse zzso Thirty-one percent of the zzso injections were associated with an adverse zzso In comparison, zzso of zzso injections and zzso of zzso injections were associated with at least one adverse zzso 

zzso was safe and zzso with a safety profile similar to that of zzso 

